The 29th International Symposium on Infections in the Critically Ill Patient (ISICIP), one of the most relevant scientific events worldwide in the field of severe infections and intensive care medicine, will this year count on the official sponsorship of Viva In Vitro as a Gold Sponsor.
The symposium will take place on October 16 and 17, 2025, in Barcelona, and will bring together a distinguished panel of medical professionals, researchers, clinicians, and international experts to discuss the latest advances in sepsis, immunological biomarkers, clinical guidelines, applied artificial intelligence, and personalized medicine for critically ill patients.
The congress is supported by leading institutions such as the European Society of Intensive Care Medicine (ESICM), the European Sepsis Alliance, the International Sepsis Forum (ISF), SEPAR, and the Spanish Society of Chemotherapy.
A key event for the future of immunological diagnostics
At Viva In Vitro, we embrace this sponsorship as part of our commitment to accelerate the development of advanced diagnostic solutions in the field of sepsis and severe inflammatory diseases. Our project, VIVA-ELISA®, focused on the NLRP3 inflammasome as a biomarker for immune stratification in septic patients, will be an active part of the knowledge shared at this congress.
Participating as a Gold Sponsor also represents a recognition of the path we’ve taken so far:
Selected by the European Innovation Council (EIC Transition) as one of the 40 most disruptive European companies
Backed by the CDTI-NEOTEC program, with over €250,000 in funding for the development of our automated diagnostic device
- More than €6 million in public and private funding secured since the founding of the company
- Strategic clinical partnerships with leading university hospitals and biomedical research centers in Spain
International leaders and high-level scientific debate
The preliminary program of ISICIP 2025 is now available and features confirmed lectures by key figures in intensive care medicine and the clinical application of sepsis research, including:
Dr. Ricard Ferrer, Vall d’Hebron – and current member of Viva In Vitro’s Medical Advisory Board
Prof. Evangelos Giamarellos, National and Kapodistrian University of Athens
Dr. Michael Niederman, Weill Cornell Medical College (New York)
- Dra. Silvia De Rosa, Santa Chiara Hospital (Trento)
- Dra. Marlies Ostermann, King’s College London
- Dr. Massimo Antonelli, Policlinico Gemelli (Roma)
- Dra. Melanie Meersch-Dini, University Hospital Münster
- Otavio Ranzani, ISGlobal
- Jose Luis García-Giménez, Instituto de Salud Carlos III de Madrid
- Among others.
This international event represents a valuable opportunity to share insights, compare clinical experiences, and open new collaborations in the field of immunology applied to critical care.
For more information about ISICIP 2025 and access to the preliminary program
